Skip to main content

Aviado · Research

Longevity Daily

Friday, November 13, 2026

Today's Brief

The biggest story today comes out of Cell: researchers mapped 92 blood proteins that cross the blood-brain barrier, finding that a liver-derived protein called APOA1 maintains healthy neural connections—and that this pathway breaks down in early Alzheimer's disease. Rapamycin continues building its primate case with a reported 15% lifespan extension in marmosets, while Nature identifies a newly discovered protein, granzyme K, that drives organ aging without the inflammation signals we've been watching for. Scientific American interrogates Bryan Johnson's GLP-1 microdosing protocol. Aviado's latest deep-dive pins down the most reliable use case for alpha-lipoic acid—and flags where the evidence doesn't hold up.

10 stories2 peer-reviewed1 Aviado original

Cognitive Health & Neuroprotection

Must ReadCell· 2026-11-12

Liver Protein APOA1 Protects the Brain—and Goes Missing in Early Alzheimer's

Published in Cell, researchers identified 92 circulating blood proteins capable of crossing the blood-brain barrier, mapping for the first time how the bloodstream nourishes and protects the brain. Among them, APOA1—a protein the liver produces—was found to regulate cholesterol metabolism in astrocytes, the star-shaped cells that support and strengthen neuronal synapses. Critically, this protective transport pathway is disrupted in early Alzheimer's disease models, offering a compelling new mechanism for why the brain becomes vulnerable long before symptoms appear. The discovery points toward a new therapeutic target: restoring APOA1 delivery to the brain could help slow or prevent neurodegeneration.

Read more →
New ResearchNews-Medical· 2026-11-13

New Brain Score May Flag Your Alzheimer's Risk Before Any Symptoms Appear

Researchers have developed the ARC brain connectivity score, an imaging-based tool that distinguishes cognitively resilient brain patterns from vulnerable ones—potentially identifying Alzheimer's risk years before memory problems emerge. The score measures how brain regions communicate, using connectivity patterns that predict whether a person's aging trajectory is following a protective or pathological course. For health-conscious adults monitoring their brain health, this type of biomarker could eventually become a routine screening tool alongside existing blood tests.

Read more →

Supplements & Compounds

Evidence CheckScientific American· 2026-11-12

Microdosing Ozempic for Longevity: What the Evidence Actually Says

Bryan Johnson and other longevity influencers are taking sub-therapeutic doses of GLP-1 agonists like tirzepatide—fractions of the FDA-approved dose—claiming benefits for brain protection, inflammation reduction, and slowing aging. Scientific American examines the science, noting that anti-inflammatory and neuroprotective effects of GLP-1s are biologically plausible but almost entirely untested at microdose levels. If you're considering this trend, understand that you're operating well outside approved clinical territory, with minimal data to guide dosing, duration, or long-term safety.

Read more →
New ResearchPRNewswire· 2026-11-12

C15:0 Scores Three New Research Wins Across Heart, Metabolic, and Cognitive Health

Three new studies on C15:0—the fatty acid at the center of Fatty15—show promising results spanning heart health, metabolic function, and cognitive protection. One key finding: C15:0 activates GPR40 receptors in the gut, pancreas, and brain, triggering GLP-1 release and supporting glucose-dependent insulin secretion, a mechanism that partially overlaps with popular GLP-1 drugs. The industry-funded nature of this research warrants some caution, but C15:0 is now building a multi-system evidence base that few novel fatty acids can match.

Read more →
Aviado ResearchAviado Research· 2026-11-12

Alpha-Lipoic Acid Reliably Cuts Inflammation—But the Glutathione Story Is Complicated

Alpha-lipoic acid works in both water- and fat-based environments in your cells and theoretically recharges depleted antioxidants like glutathione back to their active forms. In practice, 600 mg daily consistently reduces CRP—a key heart disease risk marker—by 0.3–0.7 mg/L across multiple clinical studies; the glutathione boost, however, is hit-or-miss in humans, with some people seeing increases, others no change, and a few seeing decreases. For managing elevated systemic inflammation, it remains one of the more evidence-backed supplement options you can buy without a prescription.

Read the full Aviado analysis →

Research & Papers

New ResearchImmunity· 2026-11-12

Scientists Find a Hidden Driver of Organ Aging That Bypasses Inflammation

Monash University researchers publishing in Immunity have identified granzyme K—a protein secreted by immune cells—as a key driver of age-related damage to the heart, liver, and kidneys. Its mechanism is unusual: granzyme K accelerates organ aging without triggering typical inflammatory signals, which may explain why so much age-related organ deterioration has gone mechanistically undetected. In a striking proof of concept, aged mice engineered to lack granzyme K showed markedly improved heart and liver function and significantly less kidney damage.

Read more →
New ResearchModern Healthspan· 2026-11-12

Rapamycin Extends Primate Lifespan by 15% in Marmoset Study

Researcher Adam Salmon reports a 15% lifespan extension with rapamycin in marmosets—non-human primates far closer to humans than the mice previously used to establish rapamycin's longevity credentials. The finding, discussed in a Modern Healthspan interview, adds meaningful translational weight to the growing case for rapamycin as a longevity intervention. Human trials remain limited in scale, but each new primate data point narrows the gap between compelling animal evidence and actionable clinical medicine.

Read more →
Evidence CheckBrown University· 2026-11-12

Even America's Wealthiest Die Sooner Than Average Europeans, Study Finds

A Brown University study of 73,000 adults found that Americans across every income bracket die younger than their European counterparts—a sobering finding given that U.S. life expectancy hit a record 79 years in 2024. Even the wealthiest Americans fail to match average European lifespan, suggesting individual wealth and personal optimization cannot compensate for systemic factors like healthcare structure, diet norms, and social infrastructure. For longevity optimizers, the data is a pointed reminder that system-level variables may matter as much as anything on your supplement shelf.

Read more →

Lifestyle & Nutrition

New ResearchHarvard T.H. Chan School of Public Health· 2026-11-12

Valter Longo Makes the Case for Fasting-Mimicking Diet at Harvard

Longevity researcher Valter Longo told an audience at Harvard T.H. Chan School of Public Health that a five-day Fasting-Mimicking Diet (FMD), repeated several times per year, may extend lifespan and reverse signs of disease. Unlike water-only fasting, the FMD allows limited, structured calorie intake engineered to trigger the same metabolic benefits—cellular rejuvenation, reduced inflammation, and improved biological age markers—without full abstinence from food. Human trials have shown benefits including stem cell regeneration and improved metabolic health, making FMD one of the most evidence-backed dietary longevity interventions available today.

Read more →

Industry & Policy

IndustryAgelessRx· 2026-11-12

AgelessRx Launches Three New Peptides Under Its Clinical-Grade Peptide Standard

AgelessRx has introduced three new peptide therapies under its proprietary 'AgelessRx Peptide Standard,' a framework designed to bring clinical-grade rigor and transparency to the rapidly growing peptide longevity market. The company was recently named a Top 10 Milestone 2 Awardee in the $101 million XPRIZE Healthspan competition, standing out among more than 600 competing teams. The move signals growing maturation in the peptide space, with established providers beginning to set formal evidence and quality benchmarks for an industry that has largely operated without them.

Read more →